Acadia Pharmaceuticals (United States)

Recent papers from Acadia Pharmaceuticals (United States)

1. Long-Term Trofinetide Treatment Persistence and Dosing Patterns in Rett Syndrome: A Post Hoc Analysis of Linked Trial and Real-World Specialty Pharmacy DataNeurology and Therapy · 2026
2. Trofinetide treatment of Rett syndrome during routine health care: a plain language summary of the LOTUS studyFuture Rare Diseases · 2026
3. An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male ParticipantsClinical Pharmacology in Drug Development · 2026
4. A global literature review of comorbidities and concomitant supportive medications among individuals with Rett syndromeJournal of Comparative Effectiveness Research · 2026
5. Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United StatesFrontiers in Neurology · 2026
6. Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with TrofinetideAdvances in Therapy · 2026
7. Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS StudyClinical Therapeutics · 2026
8. Rett syndrome and real-world treatment patterns of trofinetide in the United StatesJournal of Medical Economics · 2026
9. Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit α3 Selective Modulator (P8-17.012)Neurology · 2026
10. Response Trajectories of Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin: An Exploratory Cluster Analysis (P11-13.006)Neurology · 2026
11. Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United StatesJournal of health economics and outcomes research · 2026
12. Utilization of Non-pharmacological Interventions in Rett Syndrome: A Systematic Review of the Literature on Supportive Care ManagementNeurology and Therapy · 2026
13. Population pharmacokinetics of remlifanserin (ACP‐204), a serotonin 2A receptor inverse agonistAlzheimer s & Dementia Translational Research & Clinical Interventions · 2026
14. Nonclinical characterization of ACP-204, a novel selective serotonin receptor subtype 2A receptor inverse agonistJournal of Pharmacology and Experimental Therapeutics · 2026
15. Adult snow bunting survival and population change from decades of monitoring effort in IcelandArctic Science · 2026
16. Pimavanserin for Irritability in Children and Adolescents With Autism Spectrum Disorder: Phase 2 Randomized TrialJournal of the American Academy of Child & Adolescent Psychiatry · 2026
17. Mindfulness-based intervention alters nonlinear heart rate variability in a pilot studyDiscover Mental Health · 2026
18. Abstract 1052: Real-world treatment patterns and outcomes reveal distinct clinical trajectories of patients with Cyclin E1-positive ovarian cancerCancer Research · 2026
19. Cost-effectiveness of treatment and care of patients with gastrointestinal inflammatory diseases: a systematic reviewJournal of Medical Economics · 2026
20. A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy AdultsAdvances in Therapy · 2026